BULLISH BUT BECOMING CLOSE TO OVERSOLD, NO NEED TO RUSH IN AT THIS CRITICAL POINT.
PULLBACK POSSIBLE FROM .65 FIB
VOLUME HAS DECLINED, BEARISH
FDA APPROVAL TIPPED TO BE RECEIVED ON NEW SUBMISSION
AVERAGE ANALYSTS PRICE TARGET $66
AVERAGE ANALYSTS RECOMMENDATION BUY
SHORT INTEREST 23%
COMPANY PROFILE
Zogenix, Inc. is a pharmaceutical companY. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.
PULLBACK POSSIBLE FROM .65 FIB
VOLUME HAS DECLINED, BEARISH
FDA APPROVAL TIPPED TO BE RECEIVED ON NEW SUBMISSION
AVERAGE ANALYSTS PRICE TARGET $66
AVERAGE ANALYSTS RECOMMENDATION BUY
SHORT INTEREST 23%
COMPANY PROFILE
Zogenix, Inc. is a pharmaceutical companY. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.